BENICIA, Calif.—InterHealth introduced Zychrome™, a form of chromium that helps maintain normal insulin and blood sugar levels. Zychrome was shown in a randomized, double blind, placebo-controlled study by the company to significantly decrease insulin resistance and fasting insulin levels in diabetic subjects. Reductions of 30 percent were seen for both insulin parameters after three months of supplementation. Zychrome also significantly decreased inflammatory cytokine TNF-α levels by 21 percent. Reductions in this metabolic marker may help lead to normal insulin and blood sugar control.
InterHealth started development of Zychrome over five years ago with the objective of creating high-quality chromium. InterHealth tested 17 different chromium complexes for optimal benefits in metabolic function and for managing insulin resistance. According to InterHealth scientist, Francis Lau, PhD, “Zychrome is a unique form of chromium, niacin and L-cysteine called chromium dinicocysteinate. “Results from our preclinical work on Zychrome, which have been published in Molecular Nutrition & Food Research, showed the utmost potential and suggested a clear advantage over other chromium forms in various metabolic parameters such as in decreasing insulin and blood sugar levels." Safety research, including a 90-day oral toxicity study demonstrating Zychrome’s broad spectrum safety, has been published in Toxicology Mechanisms and Methods.